TY  - JOUR
AU  - Martin-Broto, J
AU  - Redondo, A
AU  - Valverde, C
AU  - Vaz, M A
AU  - Mora, J
AU  - Garcia Del Muro, X
AU  - Gutierrez, A
AU  - Tous, C
AU  - Carnero, A
AU  - Marcilla, D
AU  - Carranza, A
AU  - Sancho, P
AU  - Martinez-Trufero, J
AU  - Diaz-Beveridge, R
AU  - Cruz, J
AU  - Encinas, V
AU  - Taron, M
AU  - Moura, D S
AU  - Luna, P
AU  - Hindi, N
AU  - Lopez-Pousa, A
PY  - 2017
DO  - 10.1093/annonc/mdx536
UR  - http://hdl.handle.net/10668/11695
T2  - Annals of oncology : official journal of the European Society for Medical Oncology
AB  - Patients with relapsed unresectable osteosarcoma represents an unmet need, so active and safe systemic treatments are required. Fas cell surface death receptor and mammalian target of rapamycin pathways are implicated in progressing osteosarcoma, and...
LA  - en
KW  - RRM1
KW  - gemcitabine
KW  - osteosarcoma
KW  - phase II
KW  - second-line
KW  - sirolimus
KW  - Adolescent
KW  - Adult
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Bone Neoplasms
KW  - Child
KW  - Child, Preschool
KW  - Deoxycytidine
KW  - Disease Progression
KW  - Disease-Free Survival
KW  - Female
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Osteosarcoma
KW  - Recurrence
KW  - Sirolimus
KW  - Young Adult
KW  - Gemcitabine
TI  - Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS).
TY  - research article
VL  - 28
ER  -